EGFR and colorectal carcinoma: Overexpression of EGFR in CRC (Spano et al., 2005) provides a rationale for incorporation of targeted anti-EGFR drugs, such as cetuximab and panitumumab, into a chemotherapeutic regimen and significantly improved outcomes (Karapetis et al., 2008; Bokemeyer et al., 2009).